JB: Research grants from Amgen, AstraZeneca, Bayer, Merck, Pfizer, Roche and Sanofi-Aventis to Karolinska Institutet and/or University Hospital (no personal payments); Honoraria from Roche and AstraZeneca for chairmanship and lectures at scientific meetings; consultations for Novartis, for Stratipath AB; payments to Coronis and Asklepios Cancer Research AB; stocks in Stratipath AB (the company is involved in AI based diagnostics for breast cancer); co-author on two chapters in UpToDate: 1) Deciding when to use adjuvant chemotherapy for hormone receptor-positive, HER2-negative breast cancer. The gene discussed is NR4A1; the disease is breast carcinoma.